RxDoctor Payments Data

Palashkumar Jaiswal, MD

Gastroenterology · Wichita Falls, TXNPI 1184004301

Payments from drug & device makers

$5,962in general payments, 2019–2025

Across 302 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$443
  • Takeda Pharmaceuticals U.S.A., Inc.$398
  • Johnson & Johnson$329
  • Abbott$269
  • Sanofi$262
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,940100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,962 in reported general payments places this provider in the 60th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$317,272
Medicare patients
745
Services billed
5,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab11$154,959
LinzessLinaclotide83$78,567
TrulancePlecanatide60$68,783
XifaxanRifaximin19$59,164
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates298$18,682
Colestipol Hcl142$13,803
Pantoprazole Sodium566$7,089
Omeprazole124$2,540
Ursodiol13$2,193
Dicyclomine Hcl142$1,685
Lubiprostone15$1,277
Sucralfate36$1,094
Lactulose23$973
Procto-Med HcHydrocortisone19$776
Ondansetron Hcl43$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Xifaxan$443$127,94779 claims
AbbVieLinzess$2,009$78,56783 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →